Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA awards RMAT designation to Nightstar's NSR-REP1 for choroideremia

June 15, 2018

[177Lu]3BP-227 begins phase I/II trial in advanced solid tumors expressing NTSR1

June 15, 2018

Trillium initiates phase I trial of TTI-622 in lymphoma or myeloma

June 15, 2018

Responses seen with NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma

June 15, 2018

BioClin Therapeutics presents first data from FIERCE-21 trial of B-701 plus docetaxel in mUCC

June 15, 2018

Eisai subsidiary in joint nucleic acid drug discovery research program

June 15, 2018

Arsanis outlicenses monoclonal antibodies targeting Klebsiella pneumoniae

June 15, 2018

First participant dosed in phase II study of vosoritide in infants and young children

June 15, 2018

Diamyd Medical receives approval to initiate phase I/II study of Remygen

June 15, 2018

Durvalumab shows promising PFS and tumor response rate in phase II DREAM study in mesothelioma

June 15, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.